Biotech Scan
Biotech Scan
Biotech bifurcated at extremes — MRNA and CRSP overbought (RSI 87/81), ISRG and IQV in capitulation territory (RSI 8.8/17.4). NVO collapsing -41.5% in 30 days. Gene editing broadly recovering but extended. LEGN RSI 7.5 for third consecutive scan. Two no-data tickers: DXCM, RGEN.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 BIFURCATED — Half the sector overbought (MRNA RSI 87, CRSP RSI 81), half collapsing (NVO -41.5%, ISRG RSI 8.8, IQV RSI 17.4) |
| Key insight | NVO -22.7% in 7 days is the biggest event — GLP-1 thesis cracking under competitive pressure; ISRG and IQV both in capitulation with no bottom yet |
Price Table (Validated 2026-02-26)
| Stock | Price | 7D | 30D | RSI | SMA20 | vs SMA | Status | Action |
|---|---|---|---|---|---|---|---|---|
| CRSP | $59.60 | +9.1% | +9.1% | 81.2 ↑ | $52.03 | +14.5% | 🔴 Overbought | ⚠️ Avoid |
| BEAM | $28.38 | +1.8% | -8.3% | 61.8 | $27.76 | +2.2% | 🟡 Neutral | 🔍 Watch |
| EDIT | $2.10 | +16.0% | +1.9% | 74.4 | $1.88 | +11.6% | 🟠 Near Overbought | ⚠️ Caution |
| NTLA | $13.67 | +4.8% | -2.0% | 73.0 | $12.65 | +8.1% | 🟠 Near Overbought | ⚠️ Caution |
| ALNY | $328.26 | -3.3% | -9.2% | 48.1 | $331.70 | -1.0% | 🟡 Neutral | 🔍 Watch |
| LEGN | $17.20 | +0.3% | -27.1% | 7.5 ↓ | $19.40 | -11.4% | 🔴 Capitulation | ❌ Don't Buy |
| MRNA | $51.72 | +4.1% | +7.8% | 87.1 ↑ | $45.06 | +14.8% | 🔴 Overbought | ⚠️ Avoid |
| BNTX | $108.88 | -1.4% | -7.7% | 59.1 | $109.20 | -0.3% | 🟡 Neutral | 🔍 Watch |
| LLY | $1,009.92 | -1.3% | -4.8% | 48.1 | $1,033.40 | -2.3% | 🟡 Below SMA | 🔍 Watch |
| GILD | $143.77 | -4.9% | +4.3% | 42.3 | $148.81 | -3.4% | 🟡 Cooling | 📈 Accumulate |
| BIIB | $187.64 | -2.3% | +8.4% | 52.1 | $189.68 | -1.1% | 🟡 Neutral | 🔒 Hold |
| NVO | $37.44 | -22.7% | -41.5% | 35.0 | $48.01 | -22.0% | 🔴 Breakdown | ❌ Don't Buy |
| REGN | $765.26 | -2.1% | +0.5% | 49.9 | $773.79 | -1.1% | 🟡 Neutral | 🔍 Watch |
| VRTX | $480.10 | +2.3% | +0.7% | 59.4 | $473.40 | +1.4% | 🟡 Neutral | 🔒 Hold |
| AMGN | $377.86 | +0.6% | +8.8% | 58.4 | $366.47 | +3.1% | 🟡 Neutral | 🔒 Hold |
| ISRG | $476.32 | -6.2% | -19.7% | 8.8 ↓ | $527.40 | -9.7% | 🔴 Capitulation | 🔍 Research |
| MDT | $98.61 | -0.9% | -2.0% | 36.3 | $100.61 | -2.0% | 🟡 Weak | 🔍 Watch |
| IQV | $162.31 | -2.8% | -32.2% | 17.4 ↓ | $195.64 | -17.0% | 🔴 Capitulation | 🔍 Research |
| DXCM | — | — | — | — | — | — | — | 🔍 No Data |
| RGEN | — | — | — | — | — | — | — | 🔍 No Data |
Tier Analysis
Tier 1 — Overbought / Extended (RSI 74+): Do Not Buy
MRNA (RSI 87.1, +14.8% above SMA20) RSI 87 is extreme — second-highest RSI in the entire scan. +7.8% 30D and now extended well above SMA. This is a momentum chase environment, not an entry point. Wait for RSI to reset below 60 before reconsidering.
CRSP (RSI 81.2, +14.5% above SMA20) CRSP surged +9.1% in both 7D and 30D — same move magnitude suggesting a sharp recent spike. RSI 81 with 14.5% premium to SMA20 is overextended. Gene editing narrative is bouncing hard but valuation stretch is real. Entry zone: $50-52 (SMA retest, RSI < 55).
EDIT (RSI 74.4, +11.6% above SMA20) +16% in 7 days — a massive single-week rip for a $2 stock. RSI jumped from 35 (2/22) to 74 in 4 days. Classic low-float biotech momentum. Do not chase; these moves reverse sharply.
NTLA (RSI 73.0, +8.1% above SMA20) Recovery from RSI 46 to 73 in one week. +4.8% 7D. Gene editing names moving as a pack. Overbought relative to recent base.
Tier 2 — Neutral / Holding (RSI 42-65): Monitor
GILD (RSI 42.3, -3.4% below SMA20) Pulled back from RSI 63 (2/22) to 42.3 — meaningful cooling. Now below SMA20. Defensive biotech thesis (HIV/oncology portfolio) intact. RSI < 40 would trigger a strong entry signal. Watch for continuation below $142.
BNTX (RSI 59.1, -0.3% vs SMA20) Sitting at SMA20, RSI neutral. -7.7% 30D. mRNA pipeline narrative needs a catalyst. Hold zone.
LLY (RSI 48.1, -2.3% below SMA20) GLP-1 king continues to compress from $1,061 highs. Now -4.8% 30D and below SMA. NVO's collapse (see Tier 3) validates competitive pressure concerns. LLY's moat is stronger than NVO's but the sector sentiment is cold. Watch $990-1,000 as next support.
BIIB, REGN, VRTX, AMGN — All neutral RSI (49-59), holding near SMA. Large pharma compounders in rest mode. AMGN strongest: RSI 58, +3.1% above SMA, +8.8% 30D.
ALNY (RSI 48.1, -1.0% vs SMA20) Pulled back from RSI 49 (2/22) — essentially unchanged. RNAi thesis intact but $361 highs not recovered. Holding.
MDT (RSI 36.3, -2.0% below SMA20) Medtronic weakening — RSI 36 approaching oversold. Medical devices under margin pressure. Not broken yet but trending toward an entry zone. Watch $95-96 as RSI approaches 30.
Tier 3 — Collapse / Capitulation: Avoid or Research
ISRG (RSI 8.8, -9.7% below SMA20, -19.7% 30D) RSI 8.8 is extreme capitulation — second consecutive scan at single-digit RSI. -6.2% in the last 7 days alone, still falling. -19.7% 30D while SMA is still $527. This is not a reversal yet. Prior deep dive noted thesis concerns; RSI < 10 is capitulation territory but falling knives cut deep. Research required before any entry.
IQV (RSI 17.4, -17.0% below SMA20, -32.2% 30D) IQVIA Holdings in full breakdown. -32.2% in 30 days, -17% below SMA20. RSI 17.4 is deep oversold but momentum is still strongly negative. CRO/health analytics sector facing headwinds (pharma R&D budget cuts?). Similar to ISRG — capitulation does not equal bottom. Research required.
NVO (RSI 35.0, -22.0% below SMA20, -41.5% 30D) Novo Nordisk is the most alarming data point in this entire scan. -22.7% in just 7 days. -41.5% in 30 days. RSI 35 but falling fast — was likely 60+ just weeks ago. GLP-1 competitive landscape (LLY, oral drugs, biosimilars) is destroying the NVO premium. This is a thesis crack, not a dip. Avoid unless you have a strong view on GLP-1 long-term winner dynamics.
LEGN (RSI 7.5, -11.4% below SMA20, -27.1% 30D) Third consecutive scan at RSI below 10. Flat +0.3% 7D provides zero confirmation of reversal. Company-specific collapse continues. Avoid.
Entry Zones
| Stock | Zone | RSI Trigger | Conviction | Notes |
|---|---|---|---|---|
| 🟢 ISRG | $450-$470 | RSI < 15, confirm bottom | MEDIUM | Surgical robotics monopoly — but wait for RSI reversal signal, not just low RSI |
| 🟢 IQV | $155-$165 | RSI < 20, stabilization | LOW-MEDIUM | CRO/analytics leader, -32% 30D — need thesis check on pharma R&D cuts |
| 🟡 GILD | $138-$142 | RSI < 38 | MEDIUM | Below SMA, cooling toward oversold — defensive biotech |
| 🟡 LLY | $985-$1,005 | RSI < 45 | MEDIUM | GLP-1 king at SMA support; NVO collapse adds near-term pressure |
| 🟡 MDT | $94-$97 | RSI < 33 | LOW-MEDIUM | Medical device margin pressure; wait for RSI confirmation |
| 🔴 NVO | Avoid | — | AVOID | -41.5% 30D, thesis cracking, no floor visible |
| 🔴 LEGN | Avoid | — | AVOID | RSI 7.5 third week running, no reversal signal |
| 🔴 CRSP/MRNA | Avoid | RSI > 75 | AVOID | Do not chase; wait for reset below RSI 55 |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ⚠️ AVOID | MRNA, CRSP | RSI 87/81, 14-15% above SMA, do not chase |
| ⚠️ CAUTION | EDIT, NTLA | RSI 73-74, single-week spikes, volatile |
| 🔒 HOLD | BIIB, VRTX, AMGN | Neutral RSI, near SMA, thesis intact |
| 📈 ACCUMULATE | GILD | RSI 42 cooling toward oversold, below SMA |
| 🔍 WATCH | LLY, ALNY, BNTX, REGN, MDT | Neutral; need RSI confirmation before adding |
| 🔍 RESEARCH | ISRG, IQV | Extreme oversold — but need thesis check before entry |
| ❌ DON'T BUY | NVO, LEGN | Thesis crack (NVO) and persistent collapse (LEGN) |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| NVO -22.7% in 7 days, -41.5% 30D | GLP-1 competitive disruption is real and accelerating — LLY and oral competitors are winning |
| ISRG RSI 8.8 for second consecutive scan | Capitulation zone, but still falling — surgical robotics thesis needs fresh review |
| IQV -32.2% 30D, RSI 17.4 | CRO sector pressure severe — pharma R&D spending cuts hitting IQVIA hard |
| Gene editing (CRSP, EDIT, NTLA) overbought after weeks of weakness | Short squeeze / momentum rotation, not fundamental improvement — do not read as thesis reversal |
| MRNA RSI 87 — even more extreme than last scan's 67 | Momentum stacking; retail chasing prior week's +18% move; classic blowoff setup |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Watching ISRG RSI go from 8.8 to lower without acting | Low RSI is not a buy signal alone — need confirmation (price stabilization, RSI reversal) |
| Viewing LEGN RSI 7.5 as attractive | Third week sub-10 RSI; thesis is broken, not temporarily oversold |
Open Questions
- What specifically drove NVO -22.7% in 7 days? Clinical data, competitive pricing, or FDA news?
- Is IQV weakness pharma-spending cyclical or structural (AI replacing CRO functions)?
- ISRG -19.7% 30D: is this insider selling continuation or new competitive threat emerging?
- DXCM and RGEN data missing — need to fetch these for complete biotech coverage
Related
10 eventsNo direct external sources are attached to this read.